Showing 1,539 results

Filters Content type: News, Editors' picks, About HIV Topic: Pharmaceutical industry

News and information on drug companies, the cost of therapies, patent protections and generic medicines.

New & experimental hepatitis C treatment

Pharmasset rises on new hepatitis C drug studies

Editor's pick
Bloomberg BusinessWeek
2 November 2011
New & experimental hepatitis C treatment

TMC435-Based Therapy Significantly Improved Viral Cure Rates in Patients Who Failed Prior Treatment for Hepatitis C

Editor's pick
Business Wire
2 November 2011
Pharmaceutical industry

DFH Pharma Obtains Exclusive Rights to Second-Generation HIV Maturation Inhibitor Program

Editor's pick
DFH press release
1 November 2011
New & experimental hepatitis C treatment

Pharmasset Takes Lead in Race to Develop Hep C Therapy By Pill

Editor's pick
The Street
1 November 2011
Pharmaceutical industry

Over the Next Decade, the Dominance of Bristol-Myers Squibb Company 's Atripla in the HIV Drug Market Will Be Challenged by Gilead's Quad and Janssen's Complera

Editor's pick
Business Wire
28 October 2011
Pharmaceutical industry

Gilead posts higher profit, seeks Quad approval

Editor's pick
Reuters
27 October 2011
Types of HIV tests

HIV test kit company halts production following FDA inspections

Editor's pick
MedCity News
26 October 2011
New & experimental HIV treatments

BMS to develop Reyataz fixed-dose pill with Gilead booster drug

Editor's pick
MarketWatch
26 October 2011
Pharmaceutical industry

Innovative transdermal patch for delivery of HIV medicine

Editor's pick
Science Daily
25 October 2011
New & experimental hepatitis C treatment

Vertex study will evaluate 12-week treatment period for some hepatitis C patients

Editor's pick
Boston.com
24 October 2011
New & experimental hepatitis C treatment

Abbott says hepatitis C combo may be a blockbuster

Editor's pick
Reuters
21 October 2011
Pharmaceutical industry

Abbott To Split: Two Pharmas Are Better Than One?

Editor's pick
Pharmalot
20 October 2011
Pharmaceutical industry

Gilead At Crucial Stage For Next-Era HIV Meds

Editor's pick
Investor's Business Daily
19 October 2011
Access to healthcare

Kenya: Government Grapples With Counterfeit ARVs

Editor's pick
AllAfrica
19 October 2011
New & experimental hepatitis C treatment

Roche buys Anadys for $230 million to boost hep C business

Editor's pick
PharmaTimes
18 October 2011
Pharmaceutical industry

Europe Revises ‘Advertising In Disguise’ Proposal

Editor's pick
Pharmalot
13 October 2011
Pharmaceutical industry

New Trade Deal Would Benefit Big Pharma At AIDS Programs' Expense

Editor's pick
Huffington Post
13 October 2011
Access to healthcare

Generic Companies Join the Medicines Patent Pool

Editor's pick
Medicines Patent Pool
12 October 2011
New & experimental hepatitis C treatment

Pharmasset again expands hepatitis C drug study

Editor's pick
Bloomberg BusinessWeek
11 October 2011
New & experimental hepatitis C treatment

Vertex's Hep C Drug Needs A Growth Injection

Editor's pick
The Street
11 October 2011
Pharmaceutical industry

ViiV Healthcare Starts Phase III Clinical Programme of Celsentri® (maraviroc) versus Truvada® (tenofovir + FTC), in combination with a Protease Inhibitor

Editor's pick
Business Wire
11 October 2011
Access to healthcare

Aurobindo uses patent pool for generic AIDS drugs

Editor's pick
Reuters
11 October 2011
New & experimental HIV treatments

Boehringer signs away HIV rights to focus on hep C - InPharm

Editor's pick
InPharm
7 October 2011
Pharmaceutical industry

Gilead Sciences inks licensing deal for HIV drug -

Editor's pick
Bloomberg BusinessWeek
6 October 2011